Anti-platelet agents in pediatric cardiac practice

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84875752651&partnerID=40&md5=38b1ce3e95c67a8481617a601fe78776

Keywords:

abciximab, acetylsalicylic acid, anemia, anticoagulant therapy, antithrombocytic agent, bleeding, cardiovascular stent, chickenpox, childhood disease, clopidogrel, cyanotic heart disease, dipyridamole, drug contraindication, drug efficacy, drug elimination, drug half life, drug hypersensitivity, drug mechanism, drug megadose, drug metabolism, drug safety, epistaxis, eptifibatide, gastrointestinal hemorrhage, hair loss, heart assist device, heart disease, heart failure, heart valve prosthesis, hematologic disease, heparin, human, immunoglobulin, influenza, leukocyte count, low drug dose, melena, meta analysis (topic), methotrexate, mucocutaneous lymph node syndrome, peptic ulcer, phenytoin, pulmonary shunt, randomized controlled trial (topic), recommended drug dose, review, Reye syndrome, shunt thrombosis, side effect, skin bruising, thrombocyte activation, thrombocyte aggregation, thromboembolism, ticlopidine, tirofiban, treatment indication, vasculitis, vasoconstriction, warfarin

Abstract:

Pediatric patients with a variety of congenital and acquired cardiac conditions receive antithrombotic therapy. Many of the indications are empirical, and have either not been proven in controlled studies or are extrapolated from adult studies. This article reviews the current available literature regarding the use of anti-platelet drugs in the pediatric cardiac population. Copyright © Annals of Pediatric Cardiology 2013.

Notes:

cited By (since 1996)0